GKGerald G. Krueger

Gerald G. Krueger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gerald G. Krueger has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients

    by Daniel Zaghi, Charlene Weir, Jian Ying, Christopher S Carlin, Tom Greene, Rosemary Deshazo, Kristina Callis Duffin, Gerald G Krueger

    No validated instrument exists to measure desire for improvement in psoriasis patients. To address this void, we conducted a single-center longitudinal study of 268 moderate-to-severe psoriasis patients to psychometrically validate the Desired Improvement Tool (DIT). The DIT is a single-item instrument scored 0-5 by the patient. A 0 indicates the patient is satisfied with disease level and does not desire further treatment. A 5 indicates a large amount of improvement is desired. The DIT demonstrated high test-retest reliability (Spearman, r = 0.97). Predictive and construct validity were moderate-to-high: r = 0.70 for BSA, 0.67 for PASI, and 0.56 for PGA and r = 0.67 for Life Quality Assessment (LQA), respectively. A sensitivity analysis revealed the DIT responded to changes in BSA. As a psychometrically valid tool, the DIT may guide clinical management of psoriasis patients by capturing an important clinical construct in an expedient and quantifiable manner.


    • 1 December 2014
      • Vol. 13  (12) , 1441-8

    Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

    by Alice B Gottlieb, Robert E Kalb, Richard G Langley, Gerald G Krueger, Elke M G J De Jong, Lynn Guenther, Kavitha Goyal, Steven Fakharzadeh, Marc Chevrier, Stephen Calabro, et al.

    Long-term data are essential to assess the safety of biologic agents for the treatment of psoriasis. To evaluate the incidence of adverse events of interest (AEIs), including all-cause mortality, major adverse cardiovascular events (MACE), malignancy (excluding nonmelanoma skin cancer), and serious infections (SI), in patients treated for psoriasis in clinical practice settings. PSOLAR is a large, ongoing, observational study of patients receiving, or eligible to receive, biologic or systemic therapy for psoriasis. Cumulative incidence rates of AEIs per 100 patient-years (PY) are reported across treatment cohorts: (1) infliximab, (2) ustekinumab, (3) other biologics (eg, adalimumab and etanercept), and (4) non-biologic agents. Significant predictors of each AEI were identified using Cox proportional hazards regression methodology. PSOLAR is now fully enrolled at 12095 patients followed for 31818PY. The cumulative rate was 0.46/100PY for death, 0.36/100PY for MACE, 0.68/100PY for malignancy, and 1.50/100PY for SI. Increasing age was a significant predictor of all AEIs. A history of cardiovascular disease, malignancy, and significant infection was associated with a higher risk of developing MACE, malignancy, and SI, respectively. Exposure to infliximab (Hazard Ratio [HR]=3.101, P<0.001) and exposure to other biologics (HR=1.736, P<0.001) were significant predictors of SI. Use of immunomodulators (HR=1.954, P=0.005) was a significant predictor of MACE. Compared with non-biologic therapy, the use of biologic agents was not a significant predictor of death, MACE, or malignancy. Based on PSOLAR data through 2013, no new safety concerns were observed with infliximab for all-cause mortality, MACE, or malignancy; the data suggest that infliximab was associated with serious infections.


  • Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis

    by Katrina Abuabara, Joy Wan, Andrea B. Troxel, Daniel B. Shin, Abby S. Van Voorhees, Bruce F. Bebo, Gerald G. Krueger, Kristina Callis Duffin, Joel M. Gelfand


  • Open Access

    Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting

    by Joy Wan, Joel M. Gelfand, Kristina Callis Duffin, Gerald G. Krueger, Robert E. Kalb, Jamie D. Weisman, Brian R. Sperber, Michael B. Stierstorfer, Bruce A. Brod, Stephen M. Schleicher, et al.

    Psoriasis is a common, chronic inflammatory disease of the skin and joints mediated by types 1 and 17 helper T cells.1,2 It can develop at any age, but onset most commonly occurs in young adulthood. The disease is believed to be incurable and long-term spontaneous remissions are rare. Psoriasis is associated with impairment in physical and emotional health even in patients with mild disease, and patients with psoriasis requiring systemic therapy or phototherapy (ie, those with moderate to severe disease) have an increased risk of major cardiovascular events and mortality independent of traditional risk factors.3-9


    • 1 February 2012
      • Vol. 11  (2) , 160-7

    Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.

    by Daniel Zaghi, Gerald G Krueger, Kristina Callis Duffin

    Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis. The drug's mechanism of action is derived from extensive immunologic and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, respectively, as key mediators of psoriasis. Ustekinumab is a completely human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23. The drug has demonstrated efficacy, short-term safety, and convenience of use in the treatment of plaque psoriasis and psoriatic arthritis. Though long-term safety concerns remain, ustekinumab adds to the current treatment armamentarium and holds promise to improve quality of life. This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clinical trials.


  • Top Cited Papers
    Open Access

    Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

    by for the Collaborative Association Study of Psoriasis, Rajan P Nair, Kristina Callis Duffin, Cynthia Helms, Jun Ding, Philip E Stuart, David Goldgar, Johann E Gudjonsson, Yun Li, Trilokraj Tejasvi, et al.

    The Collaborative Association Study of Psoriasis, in partnership with the Genetic Association Information Network (GAIN), reports a genome-wide association study for psoriasis. They identify new replicated associations that highlight a role for the IL-23 and NF-κB pathways in psoriasis susceptibility. Psoriasis is a common immune-mediated disorder that affects the skin, nails and joints. To identify psoriasis susceptibility loci, we genotyped 438,670 SNPs in 1,409 psoriasis cases and 1,436 controls of European ancestry. We followed up 21 promising SNPs in 5,048 psoriasis cases and 5,041 controls. Our results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 × 10−8). Loci with confirmed association include HLA-C, three genes involved in IL-23 signaling (IL23A, IL23R, IL12B), two genes that act downstream of TNF-α and regulate NF-κB signaling (TNIP1, TNFAIP3) and two genes involved in the modulation of Th2 immune responses (IL4, IL13). Although the proteins encoded in these loci are known to interact biologically, we found no evidence for epistasis between associated SNPs. Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders.


    • 1 July 2008
      • Vol. 35  (7) , 1449-53

    Genetics of psoriasis and psoriatic arthritis: update and future direction.

    by Kristina Callis Duffin, Vinod Chandran, Dafna D Gladman, Gerald G Krueger, James T Elder, Proton Rahman

    Psoriasis and psoriatic arthritis (PsA) both have substantive genetic determinants. Numerous candidate regions and genes have now been replicated in disease susceptibility, and to a lesser extent in disease expression, in both disease entities. Intensive efforts are now under way or are being planned to perform genome-wide association scans (GWAS) in psoriasis and PsA. A major determinant of success for GWAS is likely to be accumulation of multiple large well-phenotyped cohorts, sophisticated data management, and verification of the findings. At the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members of the GRAPPA genetics committee presented a discussion of the genetics of psoriasis and PsA, including future trends. This article is a summary of that presentation and a review of the literature.


    • 1 July 2008
      • Vol. 35  (7) , 1458-63

    Clinical and genetic registries in psoriatic disease.

    by Dafna D Gladman, Proton Rahman, Gerald G Krueger, Philip J Mease, Abrar A Qureshi, Jan P Dutz, Ulla Lindqvist, Sueli Carneiro, Philip S Helliwell, Ilona Ujfalussy, et al.

    Clinical and genetic registries are an important tool in studying psoriasis and psoriatic arthritis (PsA). They assist in delineating disease features and are crucial in defining phenotype and identifying genetic and other markers of disease expression. At the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members of the clinical registries and genetics committees described several ongoing registries, including their construction, protocols, and some results from their analyses. In breakout groups, members discussed data issues, including identification of core datasets, ownership, and how to share data; and ethical issues and possible sources of funding for registries. Proceedings of these meetings are summarized.


    • 1 May 2007
      • Vol. 34  (5) , 1159-66

    Outcome measures in psoriatic arthritis.

    by Dafna D Gladman, Philip J Mease, Paul Healy, Philip S Helliwell, Oliver Fitzgerald, Alberto Cauli, Ennio Lubrano, Gerald G Krueger, Désirée Van Der Heijde, Douglas Veale, et al.

    Psoriatic arthritis (PsA), an inflammatory arthritis associated with psoriasis usually seronegative for rheumatoid factor, has emerged as a more common and severe disease than previously appreciated. The disease is multifaceted. Thus the assessment of PsA requires attention to peripheral joint involvement, axial disease, dactylitis, and enthesitis, as well as the skin manifestations. In addition, the assessment of patient reported features such as patient assessment of disease activity, pain, fatigue, quality of life, and the new concept of participation are important. The assessment of damage and the assessment of tissue histology are also important outcome measures. This article summarizes these features of PsA as well as current knowledge on the instruments available for the assessment of these domains.